Stock Trading Canary
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 7Developing evidence | 53.8% (7/13) | 71.4% (5/7) | +5.7% | +4.2% | -15.0% |
| 20D | 7Developing evidence | 53.8% (7/13) | 57.1% (4/7) | +10.6% | +11.8% | -29.3% |
| 60D | 3Small sample | 27.3% (3/11) | 33.3% (1/3) | -7.2% | +5.4% | -14.1% |
| 120D | 1Small sample | 14.3% (1/7) | 0.0% (0/1) | -35.8% | -35.8% | -35.8% |
COMPANY RESEARCH
Aspen Neuroscience, Inc.
ASPE · United States · Healthcare
Insider Signal
Snapshot: 05 Nov 2026 · 180-day research window
- Insider Signal
- 86.0 / 100 Research score, not a buy recommendation
- Reported buyers
- 4 180-day scoring window
- Net purchases
- 68.00m USD 180 days · purchases less sales
- Latest disclosure
- 2026-11-04 Publication date
What stands out
- 4 reported buyers participated in qualifying purchases during the last 180 days.
Price vs insider buying
ASPE · USD● Purchase × Sale ◇ Public disclosure ▥ 15-day cluster ·
Circles and crosses mark trade dates; diamonds below the axis mark later public disclosures. The trade became public on its disclosure date. Prices are nearest-session closes, not insider execution prices. Marker sizes are not compared when values or currencies differ.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Where the evidence comes from
Independent evidence does not object: the purchases themselves carry bull lines (several insiders together, more buyers than usual here, large purchases, bought in the last two weeks); short sellers, company results were checked and none crosses a bear threshold. No data is held for: share price and trading, company actions.
- The insider purchases themselvesBullseveral insiders together, more buyers than usual here, large purchases, bought in the last two weeks3 checked, under the threshold · 3 missing
- Share price and tradingno data held
- Short sellers1 checked, under the threshold
- Company results1 checked, under the threshold · 1 missing
- Company actionsno data held
Bull case · the buying is informative
- 4 insiders bought on the same day (2026-11-02). Several people reaching the same decision at the same time is hard to put down to one person's circumstances.
- No insider bought in the 180 days before this window; 4 have bought in it. The buying is new for this company, not a habit.
- Net purchases of $68.0M equal 18% of the company's market value ($371.0M): large for the size of the business.
- The latest purchase is 3 days old (2026-11-02). The buying is current, not left over from an earlier quarter.
Bear case · discount it
Nothing held here argues against the buying. That is not the same as nothing existing: see the missing evidence below.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- Only one reading of profitability is held (profit margin <0.01%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- The 10b5-1 box of these Form 4 filings has not been read, so whether the purchases followed a pre-arranged plan is not known.
- Form 4 states the shares held after each trade. This site reads that from the SEC's quarterly data, which is published after a quarter ends, so it does not have it yet for these filings. Whether a purchase added 1% to a personal stake or doubled it is in the filing, not on this page.
Checked and under the threshold: 5
- BearThe largest buyer accounts for 29% of the value bought. Counted for the bear side from 80%.
- BearNo insider sale is recorded in the same 180 days.
- BearOver the last 5 trading days to 2026-11-05, 48% of this stock's off-exchange volume was sold short. The market's median is 47%. This is trading volume, not a position: a market maker who sells short and covers the same day is counted, so about half of all volume is short on an ordinary day. It is shown for comparison and counts for neither side.
- BearNo insider filing in the last 180 days opened a hedge on this stock.
- BearProfit margin on the latest captured figures is <0.01%. Counted for the bear side when negative.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Who is trading?
Named filings in 180 days. Purchase values are summed only when complete and in one currency.
| Insider | Transaction activity | Purchase value | Latest trade | Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTTenPercentOwner | 3 buy · 0 sell | 20.00m USD | 2026-11-02 | View transactions · 9
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL LTenPercentOwner | 1 buy · 0 sell | 18.00m USD | 2026-11-02 | View transactions · 1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCBoard member | 1 buy · 0 sell | 15.00m USD | 2026-11-02 | View transactions · 6
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thompson Peter A.Board member | 1 buy · 0 sell | 15.00m USD | 2026-11-02 | View transactions · 6
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hasnain FaheemCEO / chair | 0 buy · 0 sell | No purchases | 2026-11-02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Spaventa AndrewBoard member | 0 buy · 0 sell | No purchases | 2026-11-02 |
INSIDER SIGNAL
Score breakdown：86.0 / 100
4 insiders · 4 purchase events · $68.00m net purchases
US #11 · United States #11
WHY THIS SIGNAL?
Score anatomy
Each bar is that part's points in the score; the five parts add up to the score.
Number of buyers+28.0 / 35
How many different insiders bought within 15 days
Amount bought+24.5 / 25
The value bought, net of any insider sales
Buyers' roles+14.0 / 20
Lower in the company scores higher: in the backtest, purchases by the most senior insiders did worse
How recent+9.5 / 10
How long ago the latest purchase took place
Buying against selling+10.0 / 10
Lower when insiders also sold
What is holding the score back?
- ✓ Many buyers · 4 or more different insiders
- ✓ Buyers' roles add a lot · the buyers are below the top of the company
- ✓ Recent buying · latest purchase 2026-11-02
Buyers' roles follow the US order of roles: CEOs, chairs and 10% owners score lowest.
Buying concentration
29%
Largest buyer：ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · 20.00m USD
Purchases counted, before sales：68.00m USD
The amount at the top of the page is purchases minus sales; this one counts purchases only, in the filing currency, so the two can differ. The score counts how many people bought; this shows separately who bought the most.
This is a ranking under the current US screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 15 USD | Nov 2, 2026 |
| ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL L | 15 USD | Nov 2, 2026 |
| ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | 15 USD | Nov 2, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 4 distinct reported filers
- Peak time window
- 2026-11-02 to 2026-11-02
- Current breadth input
- 0.800 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Latest purchase counted
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · 20.00m USD · Price 15 USD · Nov 2, 2026 - 🟢 Purchase counted
ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL L · 18.00m USD · Price 15 USD · Nov 2, 2026 - 🟢 Purchase by a manager or director
ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC · 15.00m USD · Price 15 USD · Nov 2, 2026 - 🟡 1 more purchase line(s) counted, from 1 filing(s)
- 🔴 21 other line(s) are not counted, as they are not purchases the insider chose to make; 0 have a price of zero
Filing and data quality
These checks are auditable context; they do not change the rank or score.
- Identity match
- REVIEW
- Ticker / ISIN
- Ticker or ISIN missing
- Filing source links
- 27 / 27
- Median disclosure lag
- 0 days
- Latest disclosure age
- 1 days at snapshot
- Corrections / revisions
- 0
- Score-factor detail
- Saved
Insider timeline
4 insiders bought on the same day, 2 Nov: 2 Associated person, 2 Board member. That week 63 companies across United States disclosed insider purchases, an ordinary week (26 of the last 26).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
▮Purple band: several insiders bought within 15 days
The band marks the stretch with the most different buyers: at most 15 days long and at least two people. Here it is 2 Nov, with 4 insiders. Only the strongest stretch is marked. Several people deciding the same thing is harder to explain by one person's private reasons, but insiders often buy together just after a closed period ends, so compare it with the grey weekly bars.
▂Grey bars: companies across United States disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases. The purple bar is the week of the band above: 63 companies, number 26 of the last 26 weeks. If that week was a peak anyway, buying together is less special than it looks.
This company: insiders buying per month, last 12 months
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
4Nov
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | Board member | 1 | — | 15.0M USD | 2026-11-02 | — |
| Thompson Peter A. | Board member | 1 | — | 15.0M USD | 2026-11-02 | — |
| ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | Associated person | 1 | — | 20.0M USD | 2026-11-02 | — |
| ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL L | Associated person | 1 | — | 18.0M USD | 2026-11-02 | — |
Insiders' buying price vs the latest close
Insiders paid 15.00 USD a share on average (6 purchase lines, 4 buyers, 2026-11-02 – 2026-11-02). The close on 2026-11-05 was 21.6% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Buying size vs market trading
Complete price and volume history is not yet available.
Market-data coverage: 0 verified sessions · Latest session: — · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Sector context
- Buying breadth
- 4.1% (42 / 1,020 issuers)
- Sector rank
- #7 / 13
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − S&P 500 ETF (SPY adjusted close) return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 75.0% (3/4) | 33.3% (1/3) | -10.5% | -6.6% | -15.0% |
| 20D | 3Small sample | 75.0% (3/4) | 33.3% (1/3) | -11.2% | -10.0% | -29.3% |
| 60D | 1Small sample | 50.0% (1/2) | 100.0% (1/1) | +37.5% | +37.5% | +37.5% |
| 120D | 0No data | 0.0% (0/1) | — | — | — | — |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 14.3% (1/7) | 100.0% (1/1) | +7.7% | +7.7% | +7.7% |
| 20D | 1Small sample | 16.7% (1/6) | 0.0% (0/1) | -2.3% | -2.3% | -2.3% |
| 60D | 1Small sample | 16.7% (1/6) | 0.0% (0/1) | -28.6% | -28.6% | -28.6% |
| 120D | 0No data | 0.0% (0/5) | — | — | — | — |
Signal outcomes
Calculated from immutable US ranking snapshots; excess return is stock return minus SPY return. Newly saved snapshots remain pending until each forward horizon matures. This never affects the US score.
| Horizon | Status | Result |
|---|---|---|
| 5D | Awaiting maturity | — |
| 20D | Awaiting maturity | — |
| 60D | Awaiting maturity | — |
| 120D | Awaiting maturity | — |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- —
- Beta
- —
- Avg daily volume
- $10.9M
- 20-session drawdown
- —
- 60-session drawdown
- —
- Latest volume / prior median
- —
VALUATION
- Market cap
- $371.0M
- Market cap (EUR ref.)
- $330.6M
- P/E
- —
FUNDAMENTALS
- Revenue
- —
- Net income
- —
- Operating profit
- —
- Equity
- —
- Cash
- —
- Debt
- —
- Operating cash flow
- —
- Free cash flow
- —
- Profit margin
- 0.0%
- ROE
- —
- Industry
- Biotechnology
Prices to 05 Nov 2026: OpenBB/yfinance. From OpenBB/yfinance, captured 05 Nov 2026: Market cap, Profit margin, Industry. ECB EUR reference rate dated 2026-11-05; it is not a trade-date conversion. It does not affect the insider score or rank.
Regulatory filings
- Insider filing announcement · published 2026-11-04 · trade date 2026-11-02
- Insider filing announcement · published 2026-11-04 · trade date 2026-11-02
- Insider filing announcement · published 2026-11-02 · trade date 2026-11-02
Unfold all 6 filings
- Insider filing announcement · published 2026-11-04 · trade date 2026-11-02
- Insider filing announcement · published 2026-11-04 · trade date 2026-11-02
- Insider filing announcement · published 2026-11-02 · trade date 2026-11-02
- Insider filing announcement · published 2026-11-02 · trade date 2026-11-02
- Insider filing announcement · published 2026-11-02 · trade date 2026-11-02
- Insider filing announcement · published 2026-11-02 · trade date 2026-11-02
Results and insider purchases
No results announcement (8-K Item 2.02) from this company was found in its SEC filings.
Ownership and trading-plan context
| Direct / indirect ownership | Direct, Indirect, Mixed direct / indirect |
|---|---|
| 10b5-1 filing evidence | Not declared in filing field |
| Evidence retrieved | 2026-11-05T23:55:35+00:00 |
These are accession-level filing fields. Unavailable means the evidence was not fetched or parsed; it is never inferred as “No” and does not adjust the US score.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
4 qualifying purchase disclosure(s) · 6 transaction line(s)
Trade Nov 2, 2026Open market purchase
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · TenPercentOwner
Published Nov 2, 2026 · Common Stock · 66666 shares × 15.0 USD · 999990.0 USD
Open filingTrade Nov 2, 2026Open market purchase
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · TenPercentOwner
Published Nov 2, 2026 · Common Stock · 66667 shares × 15.0 USD · 1000005.0 USD
Open filingTrade Nov 2, 2026Open market purchase
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · TenPercentOwner
Published Nov 2, 2026 · Common Stock · 1200000 shares × 15.0 USD · 18000000.0 USD
Open filingUnfold all 3 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-02 | 2026-11-02 | ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL L | TenPercentOwner | Open market purchase | Common Stock | 15.0 USD | USD | 1200000 | 18000000.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | Director,TenPercentOwner | Open market purchase | Common Stock | 15.0 USD | USD | 1000000 | 15000000.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | Thompson Peter A. | Director,TenPercentOwner | Open market purchase | Common Stock | 15.0 USD | USD | 1000000 | 15000000.0 USD | Open filing |
Showing 6 of 6 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 21 other transaction(s)
Trade Nov 2, 2026Conversion of derivative security
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · TenPercentOwner
Published Nov 2, 2026 · Common Stock · 187182 shares × — · 0.0 USD
Open filingTrade Nov 2, 2026Conversion of derivative security
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · TenPercentOwner
Published Nov 2, 2026 · Common Stock · 298258 shares × — · 0.0 USD
Open filingTrade Nov 2, 2026Conversion of derivative security
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · TenPercentOwner
Published Nov 2, 2026 · Common Stock · 286304 shares × — · 0.0 USD
Open filingUnfold all 18 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-02 | 2026-11-02 | ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 295490 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-02 | ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 259948 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-02 | ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 214355 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-02 | Hasnain Faheem | Executive Chair | Conversion of derivative security | Common Stock | — | USD | 14913 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-02 | Hasnain Faheem | Executive Chair | Conversion of derivative security | Common Stock | — | USD | 14316 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-02 | Hasnain Faheem | Executive Chair | Conversion of derivative security | Common Stock | — | USD | 7120 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-02 | Spaventa Andrew | Director | Conversion of derivative security | Common Stock | — | USD | 70194 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-02 | Spaventa Andrew | Director | Conversion of derivative security | Common Stock | — | USD | 180221 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 196541 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 642745 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 616984 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 625743 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 507119 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | Thompson Peter A. | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 196541 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | Thompson Peter A. | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 642745 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | Thompson Peter A. | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 616984 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | Thompson Peter A. | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 625743 | 0.0 USD | Open filing |
| 2026-11-02 | 2026-11-04 | Thompson Peter A. | Director,TenPercentOwner | Conversion of derivative security | Common Stock | — | USD | 507119 | 0.0 USD | Open filing |
Showing 21 of 21 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Follow new disclosures
Subscribe to new United States disclosures. These are market-wide RSS feeds, not company-specific alerts.
Model & Sources
Signal history
86.0 / 100
Latest recorded score
↑ +14.1 ptssince the first recorded snapshot on 2026-11-04; 1 calendar days observed
- Recorded snapshots
- 2
- First snapshot
- 2026-11-04
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 71.9
- 86.0
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-11-04 | 71.9 |
| 2026-11-05 | 86.0 |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.800 | 28.0 |
| Qualified-buy size | 25% | 0.980 | 24.5 |
| Role informativeness (inverted) | 20% | 0.700 | 14.0 |
| Recency | 10% | 0.951 | 9.5 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
Snapshot & identity
- Snapshot date
- 2026-11-05
- Ticker
- ASPE
- ISIN
- —
- Sector
- Healthcare
- Industry
- —
Company logos by Parqet
How to read Form 4 transaction codes
| Code | Interpretation | Screen treatment |
|---|---|---|
| P | Open-market / private purchase | Buy evidence when the security is qualifying equity |
| S | Sale | Sell evidence when the security is qualifying equity |
| A | Grant / award | Context only |
| F | Tax-related withholding | Context only |
| M | Option exercise | Context only |
| G | Gift | Context only |
| J / L | Other / non-directional | Context only |
P/S rows for options, warrants, compensation units and debt remain visible for audit but are excluded from equity scores and quotes.